Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms
Harmony Biosciences 開始治療普拉德威利綜合症症狀的 Pitolisant 三期試驗
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊